Quarterly Result30 Oct 2026, 05:31 pm
Lyka Labs Declares Q2 FY27 Unaudited Results, Approves Director Re-appointment
AI Summary
Lyka Labs Ltd announced its unaudited financial results for the second quarter ended September 30, 2026, both standalone and consolidated. The Board of Directors also approved the draft notice for a postal ballot to seek shareholder consent for the re-appointment of Mr. Neeraj Golas as an Independent Director for a period of three years, commencing January 16, 2027. The company operates in the Pharmaceuticals segment. The statutory auditors have provided an unqualified conclusion on the financial results.
Key Highlights
- Board approved unaudited financial results for Q2 FY27.
- Shareholder approval sought for director re-appointment via postal ballot.
- Mr. Neeraj Golas to be re-appointed as Independent Director.
- Company operates in the Pharmaceuticals segment.
- Auditors provided an unqualified conclusion on results.
Price Impact
More from LYKALABS